Knight Therapeutics (TSE:GUD) Reaches New 1-Year High - What's Next?

Key Points

• Knight Therapeutics Inc. reached a new 52-week high trading at C$6.51, with the last trade at C$6.48 and a volume of 284,474 shares.
• Analyst ratings show a consensus of "Buy" with a price target of C$7.15, indicating positive outlook from investment analysts.
• The company has a market capitalization of C$655.45 million and notable financial ratios, including a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as C$6.51 and last traded at C$6.48, with a volume of 284474 shares. The stock had previously closed at C$6.45.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$6.50 price objective on Knight Therapeutics and gave the company a "buy" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of C$7.15.

Knight Therapeutics Stock Performance

The firm has a 50-day moving average of C$6.11 and a two-hundred day moving average of C$5.93. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The company has a market capitalization of C$655.45 million, a PE ratio of -21.63, a PEG ratio of -1,013.50 and a beta of 0.50.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.